These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease. Nolan BE; Wang Y; Pary PP; Luban NLC; Wong ECC; Ronis T Transfusion; 2018 Nov; 58(11):2564-2571. PubMed ID: 30265742 [TBL] [Abstract][Full Text] [Related]
3. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease. Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843 [TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for the treatment of Kawasaki disease. Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415 [TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904 [TBL] [Abstract][Full Text] [Related]
6. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M; Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183 [TBL] [Abstract][Full Text] [Related]
8. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials. Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339 [TBL] [Abstract][Full Text] [Related]
9. Kawasaki disease: a comprehensive review of treatment options. Patel RM; Shulman ST J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265 [TBL] [Abstract][Full Text] [Related]
10. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370 [TBL] [Abstract][Full Text] [Related]
11. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more. Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279 [TBL] [Abstract][Full Text] [Related]
12. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders. Markvardsen LH; Christiansen I; Harbo T; Jakobsen J Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709 [TBL] [Abstract][Full Text] [Related]
13. Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan. Takeuchi M; Ito S; Nakamura M; Kawakami K Paediatr Drugs; 2018 Dec; 20(6):585-591. PubMed ID: 30345488 [TBL] [Abstract][Full Text] [Related]
14. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910 [TBL] [Abstract][Full Text] [Related]
15. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S; Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057 [TBL] [Abstract][Full Text] [Related]
16. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. Tse SM; Silverman ED; McCrindle BW; Yeung RS J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960 [TBL] [Abstract][Full Text] [Related]
18. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study. Iwashima S; Kimura M; Ishikawa T; Ohzeki T Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105 [TBL] [Abstract][Full Text] [Related]
19. Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease. Van Anh KY; Shah S; Tremoulet AH Front Pediatr; 2020; 8():146. PubMed ID: 32318529 [No Abstract] [Full Text] [Related]
20. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study]. Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]